Imagine HIV patients needed to take their antiretroviral therapies not every day, not even every month, but every two months. A GlaxoSmithKline two-drug injectable regimen that’s already under review by the FDA for monthly use could soon turn it into
read morePfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to a new move from the FDA, they might not have to wait that long. Wednesday, the agency bestowed priority review on their application for
read moreEarlier this month, amid a deadly dengue outbreak, it looked as if the Philippines might start using Sanofi’s Dengvaxia again. But that’s off the table because Sanofi failed to live up to its post-marketing commitments, health officials there said this
read moreFibroGen has not even filed its AstraZeneca-partnered oral anemia drug roxadustat for U.S. regulatory approval. But now, with a second nod in China, the blockbuster hopeful is allowed to treat all chronic kidney disease patients with anemia, regardless of whether
read moreTwenty years after its founding, England’s National Institute for Health and Care Excellence has established itself as perhaps the world’s most prominent cost-effectiveness watchdog. Now, the only leader it’s known will step down from his post. More: Dillon, who shaped
read moreBack in February, the companies revealed results from the Phase III ARCHES trial in men with mHSPC. More: Priority Review awarded to Xtandi for prostate cancer Source: News
read more© 1994 - 2026 B.M. Pharmaceuticals